Figure 5. Cisplatin modulates BTG2 expression depending on DNA fragment 173 to −82 bp upstream of BTG2 gene p53-dependently or p53-independently in prostate carcinoma cells.

Luciferase activity of nested deletion or mutation constructs BTG2 reporter vectors-transfected LNCaP (a) or PC-3 (b) cells after treatment of 40 μM of cispalatin (black bars) or control-solvent (white bars). X represented the mutation of p53 response element. Each value is the % in relation to the control solvent-treated group. Data are presented as the mean percentage ± SE (n = 6). (**P < 0.01).